|
|
|
|
|
|
|
|
|
|
|
03.06.25 - 13:03
|
Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics (Business Wire)
|
|
|
Acquisition further expands Bruker's multiomics strategy with biocrates metabolomics kits and assays, and related software and research servicesINNSBRUCK, Austria--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (NASDAQ: BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed.
biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide. The biocrates kits cover over 1,000+ metabolites from more than 40 metabolite classes, and the biocrates metabolomics technology platform combines innovative sample preparation, metabolite identification, and data analysis.
The acquisition of biocrates further enhances Bruker's MS-based metabolomics solutions. It also supports Bruker's expansion into multiomics solutions, including instruments, reagents, software, and research services, buil...
|
|
|
01.06.25 - 12:01
|
Bruker launches QSee™ in partnership with Polymer Factory (Cision)
|
|
|
Bruker launches the QSee™ quality control (QC) suite of software and reference materials for automated evaluation of instrument performance and long-term monitoring via cloud-based TwinScape™ software. In partnership with Polymer Factory Sweden AB, the leading manufacturer of stable polymer-based mass spectrometry calibrants, the SpheriCal® platform has been extended to include the new QSee ™8-mix for assessment of chromatographic and mass spectrometry performance. Results are archived for comparison across time using the TwinScape™ cloud-based solution already available for proteomics....
|
|
|
|
|
|
|
15.05.25 - 13:06
|
Bruker Announces Quarterly Dividend (Business Wire)
|
|
|
BILLERICA, Mass.--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on June 27, 2025 to stockholders of record as of June 16, 2025.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as we...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.05.25 - 13:06
|
Bruker Reports First Quarter 2025 Financial Results (Business Wire)
|
|
|
Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific Instrument (BSI) segment organic revenue up 5.1%
Q1 2025 GAAP diluted EPS $0.11; non-GAAP diluted EPS $0.47, down 11.3% yoy on M&A headwinds
Guidance on organic revenue and EPS adjusted for US policy changes and tariff headwinds. Updated FY 2025 guidance:
Revenue $3.48 to $3.55 billion, up 3.5% to 5.5%, incl. organic growth of 0% to 2%
Non-GAAP EPS $2.40 to $2.48, growth of 0% to 3% yoy
BILLERICA, Mass.--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for its first quarter ended March 31, 2025.
Frank H. Laukien, Bruker's President and CEO, commented: “Bruker had a solid start to 2025 with double-digit reported and CER revenue growth, 5.1% organic revenue growth in our BSI segment, and better operating margin performance than expected - all on strong execution, despite uncertainties in key markets....
|
|
|
|
|
|
|
16.04.25 - 12:03
|
Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring (Business Wire)
|
|
|
Bruker and RECIPE are pioneering the high-throughput 'chrom-free' ClinDART triple-quad MS platform for robust and cost-effective therapeutic drug monitoring assays
MUNICH--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (NASDAQ: BRKR) today announced a majority investment in RECIPE Chemicals + Instruments GmbH, based in Munich, Germany. RECIPE is a leading European provider of vendor-agnostic therapeutic drug monitoring (TDM) and other clinical in vitro diagnostic kits for LC-MS/MS, HPLC, and ICP-MS assays.
Financial details of the transaction were not disclosed. RECIPE has over 60 employees and continues to operate under the leadership of Managing Director Dr. Gernot Wolfram. With more than 40 years of experience, RECIPE is a highly respected, profitable company with 2024 revenues of more than fifteen million dollars.
The majority investment and strategic collaboration immediately enhances Bruker's capabilities in small molecule clinical diagnostic assays with RECIPE's ClinMASS® kits for Bruker's ...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
